Medtronic's VenaSeal Posts 88% Ulcer Healing as New Trial Chief Takes the Reins at ENDURANCE
Published on 10/07/2026 at 15:01 | Editorial boerse-global.de
Medtronic is stacking up clinical evidence on two fronts at once. Long-term results for its VenaSeal closure system landed alongside word that a national principal investigator has been named for the ENDURANCE study of the Altaviva implantable tibial neuromodulation device — a double dose of scientific momentum that investors greeted with a shrug, sending the stock down 1.4% on the day to EUR 77.36.
Two years of follow-up, one clear signal
The headline numbers come from the 24-month readout of the VenaSeal Spectrum trial, which tracked 125 patients living with active venous leg ulcers. At the two-year mark, 88.1% of those ulcers had healed. The data also showed a 78% anatomical closure rate for the treated veins over the same period.
That kind of durability matters well beyond the operating room. Long-term evidence gives physicians and payers alike a reason to back a minimally invasive approach, demonstrating that its benefits hold up long after the acute treatment window closes.
A pipeline moving on several tracks
The VenaSeal results slot into a broader pattern of regulatory and clinical activity. Medtronic's IN.PACT BTK paclitaxel-coated balloon catheter, aimed at peripheral arterial disease below the knee, has picked up Breakthrough Device designation from the FDA. To build on that, the company is planning IN.PACT BTK DELTA, a global randomized pivotal trial expected to enroll roughly 400 patients.
Should investors sell immediately? Or is it worth buying Medtronic?
Elsewhere in the portfolio, the FDA cleared the Affera Prism-2 mapping software, which also carries CE marking in Europe. The PulseSelect ProxBox adapter with Proximity Indicator software has secured CE marking as well.
Funding all of this is no small undertaking. Medtronic's Impact Report for fiscal 2026 put research and development spending at $2.9 billion, a figure that has drawn attention both as a sign of ambition and as a drag on near-term earnings. During the same reporting period, the company notched more than 315 product approvals in key markets and reported reaching over 82 million patients worldwide.
The long road from data to reimbursement
For all the clinical progress, the money question lingers: how quickly can scientific wins turn into revenue? In medtech, the gap between collecting data and routine commercial use is often measured in years, and U.S. reimbursement structures make that plain.
The American Medical Association approved new Category I CPT codes for the Altaviva and Symplicity Spyral systems just over a week ago, a development that nudged the share price up 0.5%. But those billing codes do not take effect until January 2028. Until then, access to broad reimbursement pools stays limited — R&D spending weighs on the present while meaningful revenue from fully reimbursed procedures remains more than a year away.
Structural shifts add another layer
Medtronic's corporate shape is changing at the same time. Roughly a week ago, the company moved a step closer to spinning off its MiniMed diabetes unit, and the stock has gained 3.0% since then.
Analysts have largely stayed constructive. RBC Capital reaffirmed its buy rating in an October 1 report, with a price target of $118.00. With a market capitalization of EUR 99.96 billion, Medtronic's breadth across therapeutic areas gives it room to set new treatment standards and capture scale — provided execution holds.
Medtronic at a turning point? This analysis reveals what investors need to know now.
What could go wrong
The risks are not hard to find. Trials the size of the planned 400-patient DELTA program, or an expanded ENDURANCE effort, demand serious capital and carry operational hurdles. Slow patient recruitment can push a launch back noticeably. Breakthrough Device status, meanwhile, is no guarantee of eventual market clearance, and disappointing interim data could trigger costly rework.
With R&D outlays already running at $2.9 billion a year, any delay in commercialization narrows the financial runway. If study results fail to convert into standard reimbursement models on schedule, investors may grow more skeptical of the persistently high R&D intensity.
The milestones that matter
Near-term, attention turns to the start of patient enrollment in the DELTA trial and further interim data from the ENDURANCE program. The bigger monetization milestone sits further out, with the new CPT codes taking effect in January 2028. As long as Medtronic keeps proving clinical superiority for products like Altaviva and holds its approval timelines, confidence in its innovation engine should hold. Let the schedule slip on flagship projects such as IN.PACT BTK, or let upcoming data come in soft, and those heavy upfront costs will start to weigh on the valuation.
Ad
Medtronic Stock: New Analysis - 7 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
